Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations

被引:3
|
作者
Galvani, Francesca [1 ]
Pala, Daniele [2 ]
Cuzzolin, Alberto [2 ]
Scalvini, Laura [1 ]
Lodola, Alessio [1 ]
Mor, Marco [1 ,3 ]
Rizzi, Andrea [2 ]
机构
[1] Univ Parma, Dipartimento Sci Alimenti & Farmaco, I-43124 Parma, Italy
[2] Chiesi Farmaceut SpA, Chem Res & Drug Design Dept, I-43122 Parma, Italy
[3] Univ Parma, Microbiome Res Hub, I-43124 Parma, Italy
关键词
TARGET RESIDENCE TIME; DIARYL IMIDAZOLIDIN-2-ONE DERIVATIVES; ACCELERATED MOLECULAR-DYNAMICS; DISSOCIATION RATE; BINDING-KINETICS; DRUG; MECHANISM; DISCOVERY; DESIGN; SELECTIVITY;
D O I
10.1021/acs.jcim.3c00042
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The residence time (RT), the time for which a drug remains bound to its biological target, is a critical parameter for drug design. The prediction of this key kinetic property has been proven to be challenging and computationally demanding in the framework of atomistic simulations. In the present work, we setup and applied two distinct metadynamics protocols to estimate the RTs of muscarinic M3 receptor antagonists. In the first method, derived from the conformational flooding approach, the kinetics of unbinding is retrieved from a physics-based parameter known as the acceleration factor alpha (i.e., the running average over time of the potential deposited in the bound state). Such an approach is expected to recover the absolute RT value for a compound of interest. In the second method, known as the tMETA-D approach, a qualitative estimation of the RT is given by the time of simulation required to drive the ligand from the binding site to the solvent bulk. This approach has been developed to reproduce the change of experimental RTs for compounds targeting the same target. Our analysis shows that both computational protocols are able to rank compounds in agreement with their experimental RTs. Quantitative structure-kinetics relationship (SKR) models can be identified and employed to predict the impact of a chemical modification on the experimental RT once a calibration study has been performed.
引用
收藏
页码:2842 / 2856
页数:15
相关论文
共 50 条
  • [41] M3 muscarinic receptor expression on suburothelial interstitial cells
    Grol, Simone
    Essers, Paul B. M.
    van Koeveringe, Gommert A.
    Martinez-Martinez, Piluca
    de Vente, Jan
    Gillespie, James I.
    BJU INTERNATIONAL, 2009, 104 (03) : 398 - 405
  • [42] Structure and transcription of the human m3 muscarinic receptor gene
    Forsythe, SM
    Kogut, PC
    McConville, JF
    Fu, YP
    McCauley, JA
    Halayko, AJ
    Liu, HW
    Kao, A
    Fernandes, DJ
    Bellam, S
    Fuchs, E
    Sinha, S
    Bell, GI
    Camoretti-Mercado, B
    Solway, J
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 26 (03) : 298 - 305
  • [43] The M3 Muscarinic Acetylcholine Receptor Promotes Epidermal Differentiation
    Duan, Junyan
    Grando, Charles
    Liu, Shuman
    Chernyavsky, Alex
    Chen, Jefferson K.
    Andersen, Bogi
    Grando, Sergei A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : 3211 - +
  • [44] DIFFERENTIAL INVERSE AGONISM AT THE HUMAN MUSCARINIC M3 RECEPTOR
    Casarosa, Paola
    Kiechle, Tobias
    Bakker, Remko A.
    METHODS IN ENZYMOLOGY, VOLUME 485: CONSTITUTIVE ACTIVITY IN RECEPTORS AND OTHER PROTEINS, PART B, 2010, 485 : 81 - 101
  • [45] Regulation of human oligodendrocyte differentiation by muscarinic M3 receptor
    Vedia, Bansi H.
    Pol, Suyog U.
    O'Bara, Melanie A.
    Sim, Fraser J.
    FASEB JOURNAL, 2012, 26
  • [46] Distribution of muscarinic receptor subtype M3 in melanomas and their metastases
    Oppitz, Matthias
    Busch, Christian
    Garbe, Claus
    Drews, Ulrich
    JOURNAL OF CUTANEOUS PATHOLOGY, 2008, 35 (09) : 809 - 815
  • [47] Novel derivatives of tolterodine in hunt for M3 selective muscarinic antagonists.
    Kumar, N
    Sarma, PKS
    Kaur, K
    Aeron, S
    Dutt, A
    Bruhaspathy, M
    Shetty, S
    Gupta, S
    Chugh, A
    Gupta, JB
    Mehta, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U58 - U58
  • [48] M2 AND M3 MUSCARINIC RECEPTOR EXPRESSION IN BLADDER TUMOR
    Asutay, Mehmet Kazim
    Aydin, Banu
    Toper, Hasan
    Filinte, Deniz
    Cabadak, Hulya
    Tinay, Ilker
    JOURNAL OF UROLOGY, 2018, 199 (04): : E778 - E778
  • [49] Is the m3 muscarinic receptor involved in desensitization of the cardiac muscarinic K+ current?
    Shui, Z
    Yamanushi, TT
    Boyett, MR
    JOURNAL OF PHYSIOLOGY-LONDON, 2001, 536 : 14P - 15P
  • [50] Pseudo-noncompetitive antagonism of M1, M3, and M5, muscarinic receptor-mediated Ca2- mobilization by muscarinic antagonists
    Kukkonen, JP
    Näsman, J
    Rinken, A
    Dementjev, A
    Åkerman, KEO
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 243 (01) : 41 - 46